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ABSTRACT (224 words) 18 
CD8+ T cells specific for pp65, IE1 and IE2 are present at high frequencies in HCMV 19 
seropositive individuals and these have been shown to have phenotypes associated 20 
with terminal differentiation, as well as both cytokine and proliferative dysfunctions, 21 
especially in the elderly. However, more recently, T cell responses to many other 22 
HCMV proteins have been described but little is known about their phenotype and 23 
function.  Consequently, in this study, we chose to determine the diversity of HCMV 24 
specific CD8+ T cell responses to eleven HCMV ORFs in a cohort of donors aged 20 25 
– 80 years old as well as their ability to secrete IFNγ.  Finally, we also tested their 26 
functional anti-viral capacity using a novel viral dissemination assay. 27 
We identified substantial CD8+ T cell responses by IFNγ ELISPOT assays to all 28 
eleven of these HCMV proteins and, across the cohort, individuals displayed a range 29 
of responses from the tightly  focused to highly diverse which  were stable over time. 30 
CD8+ T cell responses to the HCMV ORFs were highly differentiated and 31 
predominantly CD45RA+, CD57+ and CD28-, across the cohort. These highly 32 
differentiated cells  had the ability to inhibit viral spread even following direct ex-vivo 33 
isolation. Taken together, our data argue that HCMV specific CD8+ T cells have 34 
effective anti-viral activity irrespective of the viral protein recognized across the 35 
whole cohort and despite viral immune evasion. 36 
 37 
IMPORTANCE 38 
Human cytomegalovirus (HCMV) is normally carried without clinical symptoms and is 39 
widely prevalent in the population, however, it often causes severe clinical disease in 40 
individuals with compromised immune responses. HCMV is never cleared after 41 
primary infection but persists in the host for life. In HCMV carriers, the immune 42 
response to HCMV includes large numbers of virus-specific immune cells and the 43 
virus has evolved many mechanisms to evade the immune response. While this 44 
immune response seems to protect healthy people from subsequent disease the 45 
virus is never eliminated. It has been suggested that this continuous surveillance by 46 
the immune system may have deleterious effects in later life. The data presented in 47 
this paper examines immune responses from a cohort of donors and shows that 48 
these immune cells are effective at controlling the virus and can overcome the 49 
viruses lytic cycle immunevasion mechanisms. 50 
  51 
INTRODUCTION 52 
The β herpes virus human cytomegalovirus (HCMV) is a common infection 53 
worldwide (1). After primary infection, the virus establishes life-long persistence in 54 
individuals at least in part due to its ability to undergo latent infection in pluripotent 55 
CD34+ stem cells in the bone marrow and the myeloid cell lineages derived from 56 
them (2).  Both primary infection with HCMV and its long-term persistence is largely 57 
sub-clinical for the majority of individuals. However, infection whether due to primary 58 
infection, reactivation from latency or superinfection in the immunocompromised or 59 
immature (such as HIV/AIDS patients, transplant patients or the foetus in utero, 60 
respectively) can be life threatening (1).  Primary HCMV infection of an otherwise 61 
healthy host elicits responses from both the innate and adaptive arms of the immune 62 
system and evidence from patients undergoing bone marrow and stem cell 63 
transplantations has shown that the generation of HCMV specific CD4+ and CD8+ T 64 
cell responses is crucial for successful control of virus infection (3-7). This 65 
importance of T cell responses is further supported by evidence from the murine 66 
model of MCMV infection, where transfer of immediate early (IE) antigen specific 67 
CD8+ T cells into animals with an ablated immune system was protective from viral 68 
challenge (8).  Other murine studies have also shown that removal of CD4+ T cells 69 
from mice leads to reactivation of virus resulting in disease (9). Additionally, CD8+ T 70 
cells also prevent lethal infection of mice with MCMV in the absence of CD4+ T cells 71 
(10, 11). 72 
 73 
It is now well established that there are high frequency cytomegalovirus specific 74 
CD8+ T cell responses directed towards the pp65 (UL83) and IE1 (UL123) viral 75 
proteins in the majority of  HCMV seropositive individuals (4, 12-15).  Although the 76 
responses to pp65 and IE1 are immunodominant and large, in most individuals there 77 
are CD8+ specific T cell responses to numerous other HCMV proteins (16) such that 78 
the frequency of the total CD8+ T cell response to HCMV in infected individuals has 79 
been estimated to comprise up to 10% of the total CD8+ T cell compartment in 80 
peripheral blood (16).    81 
 82 
As a consequence of HCMV infection, it has been established that the composition 83 
of the T cell repertoire is altered resulting from virus specific cells undergoing major 84 
expansions  which has been linked to the concept of “memory inflation” described in 85 
the murine model of MCMV (17) (18).  The CD8+ IE and pp65 specific T cells that 86 
have been studied have a phenotype that has been linked to terminal differentiation 87 
as well as  dysfunction defined by  the re-expression of CD45RA (19-24); the loss of 88 
expression of the co-stimulatory molecules CD27 and CD28 (13, 21, 25-27) and  89 
expression of CD57, a marker of activation associated with differentiated T cells (21, 90 
28-30).  It has also been concluded,  from these studies, that enlarged HCMV 91 
specific CD8+ T cell populations accumulate with age which include increasing 92 
numbers of “dysfunctional” T cells as defined by their highly differentiated phenotype; 93 
loss of cytokine secretion ability and limited proliferation capacity (21, 27, 31).  These 94 
observations have led to the suggestion that the HCMV induced changes to the T 95 
cell immune system may become detrimental to individuals during their lifetime. 96 
These HCMV influenced changes to the phenotypes of host CD8+ T cells have been 97 
used to suggest on the basis of association that older seropositive individuals are 98 
more susceptible to infection, respond poorly to vaccinations and have an increased 99 
risk of mortality compared to age-matched HCMV sero-negative individuals (32-36).  100 
However, older individuals do not appear to suffer from overt HCMV disease 101 
resulting from reactivating virus or re-infection which suggests that HCMV specific T 102 
cells in these elderly donors do retain the ability to control the virus infection (37).  103 
Other studies have also challenged the dogma that these expansions of HCMV 104 
specific T cells are dysfunctional and shown that the CD45RAhi HCMV specific 105 
CD8+ T cells found in elderly donors proliferate well when given the correct co-106 
stimulation signals (38) and that the accumulating HCMV-specific CD8+ population 107 
tend to be polyfunctional as they secrete multiple anti-viral cytokines and are highly 108 
cytotoxic (39).   109 
 110 
In this study, we wished to analyse the diversity of HCMV specific CD8+ T cell 111 
responses to eleven of the highest ranked T cell ORFs in a cohort of donors with 112 
wide age variation and to determine the stability of these responses over a period of 113 
years.  Additionally, we wished to determine if T cells specific to HCMV antigens, 114 
other than pp65 and IE, displayed alternative differentiation phenotypes and, if so, 115 
how this correlated with IFNγ production, cytotoxicity and anti-viral activity.  To 116 
address this,  we  screened a donor cohort aged 24 – 80 years old and measured 117 
the CD8+  T cell response to UL83 (pp65), UL82 (pp71), UL123 (IE-1), UL122 (IE-2), 118 
UL99, UL28, UL48, US29, US32, UL55 (gB), and US3 by IFNγ ELISPOT assays.  119 
The results showed substantial CD8+ T cell responses to all of these proteins and 120 
that, over a period of three years, the diversity of HCMV protein responses in 121 
individual donors were stable.   Of the 11 ORFs analysed, we identified 6 which were 122 
recognized by the majority of the donor cohort (UL83, UL82, UL123, UL122, UL28 123 
and US3) and performed both a functional and phenotypic analysis of the CD8+ T 124 
cells responses to these ORFs.  Whilst many of the HCMV specific CD8+ T cells 125 
identified secreted IFNγ, there were a large proportion of antigen specific T cells that 126 
did not secrete the cytokine.  These analyses also revealed a highly differentiated 127 
memory T cell population common to all the ORFs studied and displayed by all 128 
individuals in the cohort. Finally, all the HCMV T cell specificities tested were able to 129 
prevent dissemination of a clinical isolate of HCMV through indicator fibroblasts.. 130 
MATERIALS AND METHODS 131 
Donor sample collection and isolation 132 
Heparinized peripheral blood was collected from healthy donors, HCMV serostatus 133 
was determined using an IgG enzyme-linked immunosorbent assay (Trinity Biotech, 134 
Didcot, United Kingdom).  Eighteen HCMV-seropositive, and 4 HCMV-seronegative 135 
donors were included in this study.  Ethical approval was obtained from the 136 
Addenbrookes National Health Service Hospital Trust institutional review board 137 
(Cambridge Research Ethics Committee) for this study. Informed written consent 138 
was obtained from all recipients in accordance with the Declaration of Helsinki 139 
(LREC 97/092).  The age range of the HCMV-seropositive donors was 24 – 80 140 
years, 5 donors were female (37.2 ± 12.3 years) and 13 male (47.5±16.9 years).  All 141 
donors were HLA typed by genotyping by the Diabetes and Inflammation Laboratory, 142 
CIMR, University of Cambridge or the NHS Tissue Typing Service, Addenbrookes 143 
Hospital, Cambridge.  Peripheral blood mononuclear cells (PBMC) were isolated 144 
using Lymphoprep (Axis-shield, Oslo, Norway) density gradient centrifugation.   145 
PBMC were either used fresh or frozen in liquid Nitrogen in a 10% DMSO (Sigma 146 
Aldrich, Poole, UK) and 90% Fetal Calf Serum (FCS) (PAA, Linz, Austria) solution. 147 
Frozen PBMC were rapidly thawed in a 37°C water bath and the freezing medium 148 
diluted into 25mls of fresh RPMI-10, centrifuged and resuspended in fresh RPMI-10 149 
before use.  150 
 151 
HCMV ORF peptide mixes 152 
11 HCMV ORFs (UL28, UL48, UL55 (gB), UL82 (pp71), UL83 (pp65), UL99, UL122 153 
(IE2), UL123 (IE1), US3, US29 and US32) were selected and consecutive 15mer 154 
peptides overlapping by 10 amino acid libraries were synthesised by ProImmune 155 
PEPScreen (Oxford, UK) from sequences detailed in the Sylwester et. al. study (16).  156 
The individual lyophilised peptides from each ORF library were reconstituted in 80% 157 
DMSO 20% RPMI 1640 (PAA laboratories, Austria) to give 40mg/ml master stock, 158 
the individual peptides were then diluted 1/40 in RPMI 1640 (unsupplemented) to 159 
give a 1mg/ml (2% DMSO) working stock.  Peptide pools were used as either entire 160 
ORF mixes at a concentration of 5µg/ml/peptide or in the case of   UL48 ORF) 10 161 
pools of 48 peptides at a concentration of 20µg/ml/peptide was used in this study.   162 
Additionally ProMix HCMVA (pp65) and Promix HCMVA (US3) peptide pools 163 
(ProImmune) were diluted to the equivalent of 20µg/ml/peptide were also used.  164 
 165 
Individual HLA typed HCMV and EBV peptides 166 
Individual HLA restricted peptides from HCMV pp65 and IE1 used in this study were 167 
HLA-A2 NLVPMVATV (pp65 495 -504aa), HLA-A1 YSEHPTFTSQY (pp65 363 -168 
373aa), HLA-A3 KLGGALQAK (IE1 184 -192aa), HLA-B7 TPRVTGGGAM (pp65 169 
417-426aa), HLA-B8 QIKVRVDMV (IE1 88-96aa) and HLA-A2 VLEETSVML (IE1 170 
316 – 324aa).  Additionally individual HLA restricted peptides from EBV BMLF-1, 171 
EBNA 3A and BZLF-1 were HLA-A2 GLCTLVAML (BMLF-1 259-267aa), HLA-A3 172 
RLRAEAQVK (EBNA 3A 603-611aa), HLA-B7 RPPIFIRRL (EBNA-3A 247-255aa) 173 
and HLA-B8 RAKFKQLL (BZLF-1 190-197aa) (all ProImmune) were also used in the 174 
study. 175 
 176 
ELISPOT assays 177 
2 x 105 – 3 x 105 PBMC or PBMC depleted of CD4+ T cells, using magnetic cell 178 
separation and anti-CD4 conjugated beads (Miltenyi Biotech, Bisley, UK), were 179 
resuspended in supplemented RPMI 1640 + 10% FCS  and IFNγ ELISPOT assays 180 
performed according to manufacturer’s instructions (eBioscience, San Diego, USA), 181 
in 96-well PVDF membrane plates (Millipore, Billerica, USA). Cells were stimulated 182 
with entire ORF mix peptides (final peptide concentration 2µg/ml/peptide) or ORF 183 
pool mix peptides (final peptide concentration 5µg/ml/peptide) at 37ºC in a humidified 184 
CO2  atmosphere for 48 hours.  All the ELISPOT assays were performed on fresh 185 
PBMC the same day as taking the blood, assays were all performed to a fixed 186 
protocol and using antibody sets from the same company as well as ELISPOT plates 187 
with identical incubation periods. PHA was used as a positive control in every assay. 188 
Developed plates were recorded by ELISPOT plate reader (AID, Strassberg, 189 
Germany) and counted using ImageJ software (National Institutes of Health, USA). 190 
 191 
Intracellular cytokine and phenotype staining 192 
2 x 106 PBMC resuspended in RPMI + 10% FCS were stimulated with ORF peptide 193 
mixes or individual mapped peptides overnight. After 2 hours incubation 5µg/ml 194 
Brefeldin A (BD Biosciences, San Jose, USA) was added for the remainder of the 195 
incubation period.  Cells were then washed and stained with a combination of 196 
surface antibodies including CD3 eFluor 650NC (eBioscience) or CD3 Qdot655 197 
(Invitrogen, Paisley, UK), CD45RA PE-Cy7, CD27 APC-eFluor 780 (eBioscience), 198 
CD8 AlexaFluor 700, CD57 AlexaFluor 647 (BioLegend, San Diego, USA), CD28 199 
PerCPCy5.5, CD45RO FITC (BD Biosciences) and LIVE/DEAD Fixable Yellow Dead 200 
cell stain (Invitrogen).  Cells were then fixed and permeabilised using FIX&PERM 201 
(ADG, Kaumberg, Austria). Peptide specific T cells were identified by the co-202 
expression of CD69 and 41BB according to established published protocols (40-43)  203 
in brief,  cells were stained intracellularly with CD69 Pacific Blue, 4-1BB PE-Cy5 204 
(BioLegend) and IFNγ PE (BD Biosciences) at 4ºC in the dark.  Samples were 205 
washed and fixed in a final 1% paraformaldehyde solution and acquired on a BD 206 
LSR Fortessa cytometer using FACSdiva software (BD Biosciences).  Data was 207 
analysed using FlowJo software (Treestar, Oregon, USA). 208 
 209 
Virus 210 
HCMV strain TB40/e UL32-GFP (gift of Christian Sinzger, University of Tübingen, 211 
Tübingen, Germany) grown in HFFs as previously described (44) was used in this 212 
study. 213 
 214 
Expansion of HCMV specific CD8+ T cells 215 
CD8+ T cells were isolated from PBMC using MACS anti-CD8 direct beads (Miltenyi 216 
Biotec, Bisley, United Kingdom) magnetic separation and then resuspended in 217 
supplemented RPMI + 10% Fetal Bovine Serum (FBS) (Invitrogen) + 10% heat 218 
inactivated autologous donor serum.  Cells were stimulated with peptide pulsed 219 
irradiated autologous PBMC in the presence of 2.5IU/ml human recombinant IL-2 220 
(National Institute for Biological Standards and Control, Potters Bar, United 221 
Kingdom)  in round bottom 96 well plates at 37ºC +5% CO2 for 10 – 14 days, fresh 222 
media was replenished every five days.  Specificity of expanded CD8+ T cell cultures 223 
using mapped peptides was determined by specific pentamer staining, cells were 224 
harvested and washed and then stained with the specific unlabelled pentamer 225 
(ProImmune), washed and then further stained with pentamer specific PE 226 
fluorophore (ProImmune) and anti-CD8 and anti-CD3 antibodies conjugated to 227 
PerCP-Cy5.5 and FITC respectively, cells were then fixed and acquired on a FACS 228 
Sort using CellQuest software (BD Biosciences) and data analysed using FlowJo 229 
software.  All expanded T cell lines were also tested for specificity using IFNγ 230 
ELISPOT assays. Briefly, resting CD8+ T HCMV specific cells were harvested and 231 
washed and then 2000 T cells were incubated in IFNγ coated PVDF membrane 232 
plates with  50 000 peptide pulsed autologous B-lymphoblastoid cell lines (LCL) and 233 
with unpulsed and mitogen stimulated controls for 48 hours at 37ºC +5% CO2.  234 
ELISPOT assays were again developed according to manufacturer’s instruction. 235 
 236 
Measurement of cytotoxicity 237 
The cytotoxic capability of the expanded HCMV specific CD8+ T cell lines was 238 
assessed using a chromium release assay.  Briefly, the rested CD8+ T cell lines 239 
were harvested, washed in acidified RPMI-10  and plated at between 15 – 80:1 E:T 240 
ratios in triplicate.  Target cells used comprised autologous LCL lines, the cells were 241 
washed in PBS and Na2Cr57O4 (Perkin Elmer) added to the cell pellet, and incubated 242 
at 37°C for 45 min, appropriate peptide or no peptide was then added to the target 243 
cells and incubated for an additional 45 min at 37°C.  Target cells were washed three 244 
times in acidified RPMI + 10% FBS medium and added to the assay plate 245 
(containing effectors, medium-only wells, and wells containing Nonidet P-40, as 246 
described above) at between 2000 – 4000 cells/well in acidified medium. Plates were 247 
incubated at 37°C for 5 h, after which 70 µl of supernatant was harvested from each 248 
well and used to quantify radioactive emission. Percent specific lysis was calculated 249 
using the following formula: percent specific lysis = 100 x (target release – 250 
spontaneous release)/(maximum release – spontaneous release). 251 
 252 
In vitro viral dissemination assay 253 
The ability of specific HCMV CD8 T cells to control the spread of HCMV virus in vitro 254 
was measured.  Autologous or partial HLA matched dermal fibroblasts were seeded 255 
in a 24 or 48 well plate to be 80-90% confluent when they were infected with TB40e 256 
UL32-GFP virus at an MOI of 0.03.  Rested HCMV specific CD8+ T cell lines were 257 
harvested, washed and resuspended in supplemented RPMI 1640 + 10% FBS then 258 
added to the infected fibroblasts 24 hours post infection at a series of T 259 
cell:Fibroblast ratios of 5, 2.5, 1.2, 0.6, 0.3:1, each experiment included a CD8+ T 260 
cell line specific to a HLA matched individual peptide from EBV (listed earlier) as a 261 
control.  In further experiments total CD8+ T cells isolated directly ex vivo from HLA 262 
matched CMV seropositive and seronegative donors were added to infected 263 
fibroblasts 24 hours post infection at a series of T cell: Fibroblast ratios of 5, 2.5, 1.2 264 
or NLV and VLE MHC Class I pentamer FACS-sorted CD8+ T cells from PBMC 265 
directly ex vivo, at T cell: Fibroblast ratios of 0.14 and 0.08. The viral dissemination 266 
assay was incubated at 37ºC +5% CO2,   assessment of viral dissemination was 267 
performed at 14 and 21 days by detection of GFP expression by both fluorescent 268 
microscopy and flow cytometry, the data was analysed and the percentage of GFP 269 
positive fibroblasts was expressed as a proportion of the Infected Control for each 270 
time point. 271 
 272 
Statistics 273 
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows 274 
(GraphPad Software, San Diego, CA). The correlation between age and the T cell 275 
response to HCMV was assessed by Pearson or Spearman correlation according to 276 
the distribution of the data.  The Wilcoxon matched pairs test was used to compare 277 
two groups of matched data and 1 way ANOVA paired Friedman test compared 278 
three groups of matched data. 279 
  280 
RESULTS 281 
HCMV specific T cell responses vary widely in their diversity between 282 
individuals.  283 
The whole proteome screen performed by Sylwester et al in 2005 (16) examined the 284 
CD8+ and CD4+ T cell responses in a cohort of 33 individuals chosen to represent a 285 
wide variety of ethnic and HLA backgrounds. Based on this analysis, we selected 11 286 
of the most frequently recognized HCMV ORFs by CD8+ T cells which included 6 of 287 
the highest frequency CD8+ T cell responses derived from a meta-analysis of data 288 
from a number of independent studies (45).  We determined the frequency of the 289 
CD8+ T cell response to each of these ORFs in a cohort of 18 CMV sero-positive 290 
donors and 4 CMV sero-negative donors using IFNγ ELISPOT assays. The 18 CMV 291 
seropositive donors represented a wide range of ages (24-77 years at the start of the 292 
study) and included 5 older donors aged between 56-77 years.  Table 1 summarises 293 
the age, gender and HLA information for each donor, and details the number of 294 
HCMV ORFs responded to by CD8+ T cells (defined by a response > 100 sfu/million 295 
above background (unstimulated) by IFNγ ELISPOT).  296 
 297 
The results showed considerable inter-donor variation in the pattern of HCMV ORFs 298 
which CD8+ T cells responded to, and that some donors mounted a more diverse 299 
response while other donors had a more focused HCMV ORF response (Figure 1A 300 
and B).  Comparison of donor age and the number of HCMV ORFs recognised also 301 
showed that the age of the donor had little impact on the number of HCMV ORFs 302 
recognised (Figure 1C). We also calculated the cumulative T cell response in each 303 
donor and correlated this with the donor age. There was a trend towards an increase 304 
in the magnitude of the CD8+ T cell response with age, but this did not reach 305 
significance for this cohort  (Spearman r=0.43, n=18) (Figure 1D).  However, when 306 
the analysis was performed on the number of ORFs that were high frequency (>1000 307 
SFU/million) (Figure 1E) this strongly correlated with age (Pearson r=0.53, n=18, 308 
p=0.02). 309 
 310 
The frequency of the CD8+ T cell response of each individual donor to each HCMV 311 
ORF was also tallied and ranked, and then subdivided into responders (> 100 312 
sfu/million by IFNγ Elispot) (Figure 1F) and the sub-set of high frequency responders 313 
(> 1000 sfu/million by IFNγ Elispot) (Figure 1G).   We identified 4 HCMV ORFs, 314 
which the majority of the donors in the cohort responded to, UL123 (IE1), UL83 315 
(pp65), UL122 (IE2), UL82 (pp71), which many donors also recognized at high 316 
frequency in addition to  UL28 and US3 which were also seen at high frequency 317 
(Figure 1F and G).  The CD8+ T cell responses to these selected ORFs are further 318 
characterised in this study.  319 
 320 
The diversity and magnitude of HCMV specific T cell responses were not 321 
significantly changed over time. 322 
T cell responses to HCMV in some individuals were clearly less diverse compared to 323 
the HCMV-specific T cell responses of others in the cohort. In order to determine if 324 
donors with less diverse responses generated responses to additional HCMV ORFS 325 
or if donors with diverse responses could lose responses we determined the stability 326 
of the CD8+ T cell responses by repeating the HCMV ORF screen analysis at 24 327 
months (n=11) (Figure 2A) and 36 months (n=7) (Figure 2B) after the original 328 
analysis. While the magnitude of individual ORF responses does vary with individual 329 
donors over the three time points at 24 months, 9/10 ORFs showed no statistically 330 
significant differences in the magnitude of the response for each donor.   A decrease 331 
in the magnitude of the IE1 (UL123) response was observed over this 2 year period 332 
(p=0.01, Wilcoxon matched pairs test),  a  further examination of this response at 36 333 
months  (1 way ANOVA paired Friedmans test) revealed that, overall, there was no 334 
statistically significant difference in the size of the IFNγ response in any of the ORFs 335 
examined.  The data also shows that no new CD8+ T cell ORF responses were 336 
observed for any individual donor in the cohort at either 24 or 36 months following 337 
the original analysis.  338 
 339 
We noted that within the data presented in Figure 2 there was an obvious change in 340 
the frequency of the response to individual HCMV ORFs for some donors.   To clarify 341 
this observation we further analysed the responses to UL83 (pp65), UL82 (pp71), 342 
UL123 (IE1) and US3 HCMV ORFs in 5 donors within the cohort which had been 343 
sampled at multiple time points over a 40 month period by IFNγ Elispot. (Figure 3A), 344 
there was a 4-fold difference in the magnitude of the detectable response to the 345 
HCMV ORF in an individual over this time period.  The specific ORF responses for 346 
donors CMV 305, CMV 300 and CMV 301 were also collated (Figure 3B).  We 347 
observed a decrease or increase across a number of HCMV ORF responses at 348 
selected time points for each donor. 349 
 350 
HCMV specific T cells are predominantly TEMRA cells irrespective of their 351 
antigen specificity  352 
Numerous studies of pp65 (UL83) and IE1 (UL123) specific T cells in the peripheral 353 
blood of healthy donors have reported that HCMV pp65 specific CD8+ T cells have a 354 
differentiated memory phenotype compared to other virus specific T cells; this is 355 
characterised by the loss of expression of the co-stimulatory molecule CD27 and re-356 
expression of CD45RA (19-23, 28, 46).  Within our donor cohort, we identified 4 357 
additional HCMV ORFs (UL122, UL28, UL82 and US3), besides UL83, UL123, 358 
which generated CD8+ T cell responses in a large proportion of subjects examined 359 
(Figure 1F and G). Consequently, we asked whether these ORF specific CD8+ T 360 
cells directed against these other HCMV ORFs had a similar memory phenotype to 361 
that previously described for pp65 and IE specific T cells. The phenotype of HCMV 362 
specific CD8+ T cells from a range of donors (encompassing the age range of the 363 
donor cohort) was determined by co-expression of 4-1BB, CD69, CD45RA and 364 
CD27 after ORF stimulation. Following the exclusion of doublet and dead cells, four 365 
memory T cell subsets were defined (Figure 4A).  A representative activation and 366 
phenotype analysis following UL28 stimulation is illustrated (Figure 4A).  To 367 
demonstrate that CD69 and 4-1BB co-expression identifies antigen specific T cells in 368 
combination with CD45RA and CD27 as memory subset markers we analysed the 369 
CD8+ T cell response from three donors taken from the cohort, in parallel cells were 370 
stained with MHC Class I pentamers containing either pp65 epitope NLV or IE 371 
epitopes (VLE and QIK) or stimulated with these peptides and identified antigen 372 
specific cells by CD69 and 4-1BB expression in combination with CD45RA and 373 
CD27 expression. The results show that the phenotypic distribution of Naïve, TEM, 374 
TCM and TEMRA identified by MHC Class I pentamers was very similar to the 375 
proportions identified by CD69 and 4-1BB expression (Figure 4B).  The size of the 376 
antigen specific T cell population identified by pentamer staining compared to that 377 
identified by CD69/4-1BB co expression was variable between the donors, the NLV 378 
response was very similar in donor CMV324 (pentamer v CD69/4-1BB, 2.5% v 379 
2.3%), in donor CMV307 the size of the pentamer population was larger than the 380 
CD69/4-1BB population (pentamer v CD69/4-1BB, 6% v 2.4%) and in donor 381 
CMV301 the pentamer population was smaller than the CD69/4-1BB population e.g. 382 
NLV (pentamer v CD69/4-1BB, 1% v 1.9%). 383 
 384 
Six donors  were analysed using 6 HCMV ORF stimulations (Figure 4C).  As 385 
expected, the results confirmed previous analyses that pp65 and IE specific T cells 386 
were predominantly TEMRA cells (CD45RA+ CD27-) (22, 38, 47, 48). However, we 387 
were also able to show that T cells specific for another immediate early antigen, 388 
US3, and another late antigen, pp71, were also dominated by TEMRA cells as well as 389 
subpopulations of TEM (CD45RA- CD27-) and TCM (CD45RA- CD27+) cells.  CD8+ T 390 
cells specific for two further ORFs, UL28 and IE2, also had a very similar pattern of T 391 
cell subset distribution.  392 
 393 
HCMV specific CD8+ T cells can secrete cytokines and are cytotoxic 394 
We also assessed the ability of the different antigen specific CD8+ T cell populations 395 
we had identified in our cohort to secrete IFNγ following ORF stimulation.  ORF 396 
reactive T cells were, again, identified by expression of 4-1BB and CD69 following 397 
the exclusion of doublet and dead cells; in addition the T cells were permeabilized 398 
and stained for intracellular IFNγ expression as a control the % IFNγ expression in 399 
cells not expressing 4-1BB and CD69 was also determined in most cases this was 400 
negative or <0.1% . The results show that all ORF specific T cells from all donors, 401 
had populations of T cells which were IFNγ positive as well as negative. In every 402 
donor, we could identify individual ORF responses in which the T cells had 403 
predominantly lost the ability to make IFNγ as well as other ORF responses where 404 
the ability to make IFNγ was predominantly retained (Table 2). 405 
 406 
As TEMRA cells are considered to be more highly differentiated, we also determined 407 
the ability of UL82, UL83, UL28, US3, UL123 and UL122-specific TEMRA (CD27-408 
CD45RA+) cells to secrete IFNγ following stimulation (Figure 5). The results show 409 
that only a proportion of these cells retained the ability to make IFNγ, however this 410 
was observed in all the donors tested.  411 
 412 
The gain of CD57 and loss of CD28 expression are also well recognized markers of 413 
the late differentiation status of TEMRA cells. Consequently, we determined the 414 
percentage of CD28- and CD57+ HCMV ORF specific TEMRA cells in each of the 415 
donors (Table 3). The results clearly show that, irrespective of antigen specificity, the 416 
majority of the TEMRA cells had lost CD28 expression and gained CD57 expression 417 
and that this occurred to the same extent in all of the donors. 418 
 419 
In addition to assessing IFNγ function of T cells specific to different HCMV ORFs, we 420 
also measured their cytotoxic capability. T cells lines specific to UL82, UL28, US3 421 
and UL122 encoded proteins were expanded in vitro. The specificity of these T cell 422 
lines was confirmed by IFNγ ELISPOT or MHC Class I pentamer specific staining 423 
(data not shown) and then they were used in chromium release cytotoxicity assays.  424 
As expected, CD8+ T cells specific for pp65 and IE1 from all donors tested elicited 425 
cytotoxicity (Figure 6).  Similarly, UL82, UL28, US3 and UL122 specific CD8+ T cells 426 
also demonstrated good cytotoxic function.  427 
 428 
HCMV specific CD8+ T cells are able to control viral dissemination in vitro 429 
We next wanted to assess the ability of individual HCMV ORF specific CD8+ T cells 430 
to recognize virus infected cells. Consequently, we developed a novel in vitro assay 431 
to measure the ability of virus specific CD8+ T cells to control the spread of HCMV 432 
virus in culture.  Primary dermal fibroblasts derived from specific donors were 433 
infected with a low MOI of a GFP-tagged clinical strain of HCMV (TB40e UL32GFP) 434 
and then co-cultured with individual ORF specific CD8+ T cells at a range of 435 
effector:target cell ratios. After 10 to 28 days of co-culture, the spread of the virus 436 
through the fibroblast layer was measured by flow cytometic analysis of GFP 437 
expression in the indicator fibroblasts.   The specificity of inhibition of HCMV spread 438 
by HCMV specific T cells was controlled for by including T cell lines specific for EBV 439 
derived from each donor in the assays.  Additionally, we included a positive control 440 
of infected fibroblasts with no T cell co-culture as well as a negative control of 441 
uninfected fibroblasts in each assay.  442 
A representative assay comparing UL83 (pp65) and UL123 (IE1) specific CD8+ T 443 
cells derived from donor 307 is illustrated (Figure 7A and B) and shows that both IE 444 
and pp65 specific T cells are highly effective at controlling spread of HCMV even at 445 
the lowest E:T ratio of 0.6:1.  Importantly, EBV specific T cells from the same donor 446 
could not inhibit HCMV spread. We repeated this analysis on pp65 and IE1 CD8+ T 447 
cell lines derived from four additional donors with similar results (Table 4).  448 
The effector T cells used in these assays were generated from resting memory cells, 449 
previously expanded in vitro, and whilst the analysis clearly shows that these in vitro 450 
generated cell lines have specificity and were able to prevent viral dissemination, the 451 
in vitro manipulation might not represent effector cells generated in vivo. To address 452 
this, we isolated total CD8+ T cells directly ex vivo, from two different HCMV 453 
seropositive and two HCMV seronegative donors for which we had also derived an 454 
autologous fibroblast cell line. Total CD8 T cells were added at E:T ratios of 5:1 and 455 
2.5:1 to the viral dissemination assays. The results show that T cells from HCMV 456 
seropositive donors prevented viral dissemination, while T cells from HCMV 457 
seronegative donors did not (Figure 7C).  We also performed this experiment using 458 
defined antigen specific T cells,   NLV pp65 specific or VLE (IE) specific T cells were 459 
isolated directly ex vivo using MHC Class I pentamers and FACS, from a HLA-A2 460 
seropositive donor and total CD8 T cells from HLA-A2 seroponegative donor and the 461 
T cells used in a viral dissemination assays. The results again show that the direct 462 
ex vivo isolated HCMV antigen specific T cells exhibited direct anti-viral function, 463 
preventing viral dissemination in these assays (Figure 7D). 464 
 465 
Finally,  we also examined the ability of CD8+ T cells specific for UL82 (Figure 8A) 466 
and US3 (Figure 8B) to prevent viral dissemination and clearly observed both US3 467 
and UL82 specific CD8+ T cells were also able to control the spread of a non-468 
attenuated, clinical strain of HCMV. It was noted that the EBV specific T cell line did 469 
show some non-specific viral control at the higher E:T ratio but this was not observed 470 
at the lower E:T ratio (Figure 8B).  471 
DISCUSSION 472 
In this study, we have investigated the T cell response to 11 HCMV ORFs in a  473 
cohort of 18 donors ranging from 20 to  80 years of age.  Within this cohort, some 474 
donors had only a small diversity of responses to HCMV ORFs whereas other 475 
donors responded to a much broader range of HCMV antigens.  There was a 476 
significant correlation between age and the number of ORFs that elicited high 477 
frequency (>1000 SFU/million) T cell responses.  The memory phenotype of CD8+ T 478 
cells specific for 6 HCMV ORFs recognized by most donors, including pp65 and IE, 479 
showed that the predominant phenotype of CD8+ T cells for all the HCMV ORFs was 480 
CD27-CD45RA+ TEMRA cells across the cohort tested. Likewise, the distribution of 481 
IFNγ expressing T cells and markers of late differentiation (presence of CD57 and 482 
loss of CD28).  Similarly, pp65 and IE specific T cells were both effective anti-viral T 483 
cells.   484 
 485 
Memory T cell “inflation” was originally reported in MCMV infection of  mice, where 486 
the magnitude of memory and long term memory T cell responses was measured 487 
following primary MCMV infection (17, 49, 50). Based on these studies, it has been 488 
suggested that the same phenomenon also occurs in the latently infected human 489 
host. However, there have been no extensive longitudinal studies on latently infected 490 
individuals and, as such, memory T cell inflation in the human host has only been 491 
inferred by analysis of donors over a cross section of ages and, almost exclusively, 492 
by examining pp65 and IE specific T cell responses (21, 31, 34, 51, 52). It is clear 493 
that elderly individuals often have high frequency pp65 and IE specific T cell 494 
responses  (21, 47, 53-57) although it is not unusual to also observe this in the 495 
young  (39). Clearly, an important issue is the use of the age of a donor to infer the 496 
length of time that individual has been carrying HCMV.  Yet it is important to note 497 
that infection in early childhood would mean that a 30 year old (classified as young) 498 
would have been carrying virus for just as long as a 75 year old who was infected in 499 
their mid-forties. Given this caveat, our data shows that the cumulative T cell 500 
frequency including HCMV ORF specificities other than pp65 and IE tends to 501 
increase with age and that the number of ORFs that are at high frequency (>1000 502 
SFU/million) was strongly correlated with age, thus supporting the idea that periodic 503 
HCMV reactivation provides antigenic stimulation to drive increased T cell 504 
responses.  505 
 Analysis of the T cell frequency to 11 different HCMV ORFs, in a number of donors 506 
at multiple time points for up to 36 months, showed that the frequency of T cells 507 
which recognised these ORFs did not show inflation and in fact demonstrated both 508 
increased and decreased frequency. A detailed analysis of some of the cohort 509 
sampled at multiple time points over 40 months confirmed that the frequency to an 510 
individual ORF in an individual donor varies with time. These observations are in 511 
complete agreement with a study published by Crough and colleagues (58) who first 512 
described this periodic fluctuation in both HCMV and EBV specific CD8+ T cells over 513 
a 9-25 week period and provided evidence of sub-clinical viral reactivation driving 514 
expansions. Clearly this fluctuation continues to occur over years, however as an 515 
important caveat,  the antigen specific frequency was determined using a functional 516 
assay (IFNγ ELISPOT) as such the fluctuations noted could be due to changes in the 517 
proportion of cells with this function rather than changes in the absolute size of the 518 
population.  Interestingly, ORFs that were not recognized in the original analysis 519 
were not recognised in analyses at later time points.  Consequently, a longitudinal 520 
study over much longer periods of time will be required in humans if the process of 521 
“memory inflation” is to be observed and the use of a more absolute measure of 522 
frequency such as MHC Class I multimers in conjunction with functional measures 523 
would be most informative .  524 
 525 
The expansion of a TEMRA CD8+ HCMV specific population has been previously 526 
reported for pp65 and IE specific T cells (14, 19, 20, 22, 23, 28, 46). Our 527 
observations also show that T cells for other HCMV ORFs show a similar expansion 528 
of this T cell phenotype across the cohort tested. It was also noted that the 529 
distribution of memory T cell phenotypes in a given donor was very similar 530 
irrespective of the ORF specificity, this was also observed with in the two donors 531 
who were analysed by MHC Class I pentamers to either IE or pp65 specific peptides 532 
both donors had similar T cell subset distributions regardless of the epitope 533 
specificity (Figure 4).  Although accumulation of TEMRA CD8+ T cells in HCMV has 534 
been associated in some studies with a loss of T cell functionality (21, 34), more 535 
recent studies from ourselves and others have shown that these T cells are actually 536 
polyfunctional as long as they are correctly co-stimulated and are able to proliferate 537 
and secrete multiple anti-viral cytokines as well as markers of cytotoxic potential (38, 538 
39). 539 
 540 
The TEMRA CD8+ HCMV specific cells for all the HCMV ORF specificities identified in 541 
this study, despite having a highly differentiated CD57+ CD28- phenotype, were also 542 
able to secrete IFNγ following antigen stimulation. The low percentage of IFNγ 543 
secretion by CMV ORF specific CD8+ T cells by some donors has been previously 544 
observed in other studies (34, 59, 60).  The changing pattern of cytokine secretion by 545 
antigen specific T cells has been proposed as a measure of the differentiation status 546 
of the memory T cell population (61-64).  In particular the loss of IFNγ secretion 547 
capacity coupled with the secretion of CC Chemokines (MIP-1beta, MIP-1alpha, and 548 
RANTES) has been associated with very late stage differentiated CD8+ T cells and 549 
has been observed principally in CMV specific CD8+ T cells (65).   550 
 551 
The relationship between HCMV T cell antigen specificity, the frequency of highly 552 
differentiated T cells and their overall anti-viral functionality with respect to the 553 
changes that are observed in elderly individuals remains unclear.  HCMV infection in 554 
the elderly has been associated with a detrimental impact on the health of elderly 555 
individuals (32-36) and it is suggested that  this may  result from the T cell response 556 
to HCMV, itself, becoming dysfunctional, with a subsequent loss of control of the 557 
virus, as well as a concomitant  degradation of the host immune system, in general, 558 
to the point when the generation of new responses are impaired (66). Despite the 559 
association of HCMV with a loss of immune function,  older sero-positive individuals 560 
do not appear to suffer from overt HCMV disease from either reactivating virus or 561 
new  infections, suggesting that HCMV specific T cells do retain the ability to control 562 
the virus (37).  T cell functional fitness is assessed as the ability of T cells to mount 563 
appropriate polyfunctional responses by multi-analyte analysis or even mediate 564 
cytotoxicity. However, this is an indirect measure of anti-viral activity and previously 565 
published assays have not, so far, used HCMV infected cells as targets. 566 
Consequently, they do not   assess functionality in a background of, for instance, the 567 
well described MHC Class I evasion mechanisms which occur during HCMV lytic 568 
infection.  569 
 570 
In our analyses, we have developed a viral dissemination assay, with T cell co-571 
culture, in order to provide a direct measure of anti-viral activity. This now allows an 572 
assessment of different HCMV ORF specificities from the same donor for their anti-573 
viral potential. Interestingly, such assays showed that T cells specific for the late 574 
antigen pp65 were as effective at preventing viral dissemination as IE specific T 575 
cells. All the pp65 and IE specific T cells derived from individual members of the 576 
cohort were effective at preventing viral dissemination.  577 
 578 
HCMV is a paradigm for viral immune evasion of T cell recognition, yet it has always 579 
been somewhat of a paradox that a virus with such an extensive array of immune 580 
evasion mechanisms elicits a very strong T cell response following primary infection 581 
(25, 28) and, likely, reactivation as immunosuppressed HCMV seropositive patients 582 
often lose the ability to control viral replication resulting in end organ disease. These 583 
observations suggest that the T cell immunity must also be effective at preventing 584 
disease following reactivation in normal healthy individuals. The data presented in 585 
this manuscript supports this conjecture as T cells specific for both early and late 586 
gene products are highly effective at preventing viral dissemination in an in vitro 587 
model and the viral immunevasion strategies appear unable to allow avoidance of T 588 
cell immune responses in the context of lytic infection.  Our view is that the real value 589 
of the T cell immune evasion functions of HCMV is to allow a latent virus in an 590 
individual cell sufficient time to undergo reactivation and assemble new virus rather 591 
than to allow unrestricted viral replication that ends up causing disease in the host 592 
upon a primary infection or following reactivation.  593 
 594 
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TABLE AND FIGURE LEGENDS 598 
Table 1 - Donor information and summary of HCMV CD8+ T cell responses. 599 
The age, gender and HLA allele typing data for 18 HCMV sero-positive and 4 sero-600 
negative donors examined in this study.  The number and identity of HCMV ORFs 601 
recognized (>100 sfu/million cells) and the high frequency ORFs (>1000 sfu/million 602 
are summarized.  603 
Table 2 Frequency of HCMV ORF specific T cells and proportion that secrete 604 
IFN γ 605 
ORF specific T cells were identified by 4-1BB and CD69 co-expression in 6 donors, 606 
IFNγ secretion was determined by intracellular staining. The percentage of HCMV 607 
ORF specific CD8+ T cells which secrete IFNγ for each donor was determined. IFNγ 608 
secretion by cells not expressing 4-1BB and CD69 unactivated (unact) was also 609 
determined. 610 
Table 3 Percentage of HCMV ORF specific CD8+ TEMRA cells with a CD28- and 611 
CD57+ phenotype 612 
ORF specific CD8+ T cells were identified by 4-1BB and CD69 expression in 6 613 
donors. The proportion of HCMV specific TEMRA cells that are CD57+ and CD28- 614 
were enumerated. 615 
Table 4 pp65 and IE1 specific CD8+ T cells control viral dissemination in an in 616 
vitro assay 617 
The percentage of TB40eUL32-GFP+ fibroblasts (expressed as a percentage of the 618 
Infected Control) present at Day 21 for UL83 (pp65) and UL123 (IE1) specific cells 619 
compared to EBV specific cells for 5 different donors examined are shown.  620 
Figure 1 – The HCMV ORF specific diversity of CD8+ T cell responses varies 621 
widely between donors.  622 
Frequency of the CD8+ T cell response to 11 HCMV ORFs in 18 donors is shown.  623 
The responses were measured by IFNγ ELISPOT and shown as sfu/million cells 624 
(spot forming unit/million cells) following the subtraction of background counts from 625 
unstimulated cells.  The donor cohort is arranged according to the age of the donor 626 
and the size of the response to each HCMV ORF is shown as a heat map (A).  The 627 
number of ORFs each donor responded to (>100 sfu/million) (B), and also plotted 628 
according to the age of the donor (C). There was no statistical correlation between 629 
age and the number of ORFs an individual recognised by Pearson correlation.  The 630 
cumulative IFNγ response to all HCMV ORFs for each donor was plotted according 631 
to donor age and this was not significantly correlated with age by Spearman 632 
correlation (D). The number of ORFs each donor responded to at high frequency 633 
(>1000 sfu/million) was also correlated with age by Pearson correlation, there is a 634 
significant increase in high frequency ORFs in older donors p=0.02  (E).  The 635 
frequency of recognition by CD8+ T cells of each HCMV ORF is shown for all 636 
responses >100 sfu/million (F) and the high frequency responses (>1000 sfu/million) 637 
(G) (a subset of the data in (F)), the HCMV ORFs were ranked according to the 638 
number of subjects responding.       639 
     640 
Figure 2 – The frequency and diversity of HCMV ORF CD8+ T cell responses 641 
was not significantly changed over time. 642 
HCMV ORF specific T cell frequency was determined for 18 donors in 2009 by IFNγ 643 
ELISPOT and then repeated for 11 donors in 2011 (24 months) and again on 7 644 
donors in 2012 (36 months).    The responses for each ORF are shown for the 24 645 
month (A) and the 36 month (B) data (2009, black; 2011, white; 2012 grey points).  646 
The positive response (100 sfu/million) cut off line is indicated on each graph.  The 647 
24 month paired data was tested using a Wilcoxon matched pairs test, significant 648 
results * (p<0.05) are indicated.  The 3 time points in the 36 month data group were 649 
tested using a 1 way ANOVA paired Friedman test which showed no significant 650 
change in the variance of the data.   651 
Figure 3 – There is fluctuation in the magnitude of an individual donor’s CD8+ 652 
T cell response to particular HCMV ORFs. 653 
HCMV ORF specific T cell frequency was determined by IFNγ ELISPOT at multiple 654 
time points over a 40 month period. The responses of 5 different donors for UL83 655 
(pp65), UL82 (pp71), UL123 (IE1) and US3 HCMV ORFs (A) show that for an 656 
individual the magnitude of the response both decreases and increases of the period 657 
of time observed.  Also the responses of donors CMV 305, CMV 300 and CMV 301 658 
to selected HCMV ORFs are shown for the same period of time (B).  The positive 659 
response (100 sfu/million) cut off line is indicated on each graph. 660 
 661 
Figure 4 – HCMV specific CD8+ T cells have a predominantly CD45RA+ CD27- 662 
(TEMRA) phenotype. 663 
PBMC were stimulated overnight with mapped HCMV ORF peptides or HCMV ORF 664 
pools in the presence of Brefeldin A.  Identification of HCMV specific CD8+ T cell 665 
responses was as shown in the example gating strategy (A); antigen specific CD8+ 666 
populations were identified by expression of 4-1BB and CD69 and 4 memory 667 
populations defined according to the expression of CD27 and CD45RA 668 
(CD27+CD45RA+, T Central Memory (TCM) (CD27+CD45RA-), T Effector Memory 669 
(TEM) (CD27-CD45RA-) and T Effector Memory CD45RA+ cells (TEMRA) (CD27-670 
CD45RA+).  Comparison of the CD27 and CD45RA phenotype of  mapped peptide 671 
stimulated 4-1BB and CD69 positive CD8+ T cells with matched pentamer identified 672 
CD8+ T cells (B).  The memory phenotype of 6 HCMV ORFs (pp65, pp71, UL28, 673 
IE1, IE2 and US3) identified by expression of CD69 and 4-1BB for 6 donors was 674 
examined the data for each ORF is arranged in increasing age order from left to right 675 
on the x-axis (C). 676 
 677 
Figure 5 – HCMV specific CD8+ T cells from 6 different ORFs had a very similar 678 
pattern of IFNγ secretion.  679 
PBMC from 6 donors were stimulated overnight with mapped HCMV ORF peptides 680 
or HCMV ORF pools in the presence of Brefeldin A.  Antigen Specific populations 681 
were identified as described in Figure 5 and briefly shown in (A), the IFNγ production 682 
by the TEMRA antigen specific CD8+ T cell subset was determined.  The proportion of 683 
the HCMV specific TEMRA population which secreted IFNγ (black) as a proportion of 684 
the total percentage of antigen specific TEMRA cells (grey) for the different HCMV 685 
ORFs examined: pp65, pp71, UL28, IE1, IE2 and US3; the data for each ORF was 686 
arranged in increasing age order from left to right on the x-axis (B).    The proportion 687 
of HCMV specific TEMRA cells which secrete IFNγ varies between donors but there 688 
was no relationship with either age or HCMV ORF specificity.   689 
 690 
Figure 6 – HCMV specific CD8+ T cells specific for pp65, IE1, pp71, UL28, US3 691 
and IE2 mediated cytotoxicity.  692 
HCMV specific CD8+ T cells were used as effector cells in chromium release assays 693 
to determine the cytotoxicity function of cells specific for pp65, IE1, pp71, UL28, US3 694 
and IE2 HCMV ORFs.  Target cells were donor matched lymphoblastoid B cell lines 695 
which were pulsed or not with mapped peptides for each donors known HCMV ORF 696 
responses.  CD8+ T cells specific to all the HCMV ORFs examined show specific 697 
lysis of peptide pulsed target cells compared to activity against unpulsed target cells.   698 
 699 
Figure 7 – Both pp65 and IE1 specific CD8+ T cells control viral dissemination 700 
in an in vitro assay. 701 
Donor matched dermal fibroblasts were infected with TB40e-UL32-GFP virus at a 702 
low MOI, HCMV specific in vitro expanded CD8+ T cells were co-cultured with the 703 
virus infected fibroblasts at a range of effector:target ratios.   The percentage of 704 
GFP+ fibroblasts was measured by flow cytometry at 14, 21 and 28 days in 705 
comparison to an uninfected, infected control and a non-specific CD8+ T cell line 706 
(EBV specific).  A representative example from Donor 307 at Day 14 of the assay, 707 
show dot plots (A) and a summarised bar chart (B) of data expressed as a proportion 708 
of the Infected control for pp65 and IE1 specific CD8+ T cells which are both equally 709 
able to control dissemination of virus.   CD8+ T cells directly ex vivo from HLA 710 
matched CMV seropositive and seronegative donors were co-cultured with the virus 711 
infected fibroblasts, the percentage of GFP+ fibroblasts as a proportion of the 712 
Infected control at Day 21 of the assay are summarised (C).  Directly ex vivo HCMV 713 
specific CD8+ pentamer sorted cells at 0.14:1 and 0.08:1 effector:target ratios were 714 
able to control the dissemination of virus, data shown at Day 21 of the assay (D). 715 
 716 
Figure 8 – UL82 and US3 specific CD8+ T cells control viral dissemination in an 717 
in vitro assay. 718 
Donor matched dermal fibroblasts were infected with TB40e-UL32-GFP virus at a 719 
low MOI, HCMV specific in vitro expanded CD8+ T cells were co-cultured with the 720 
virus infected fibroblasts at a range of effector:target ratios as described (Figure 6).  721 
Summary bar chart show the percentage of GFP+ fibroblasts present at Day 21 for 722 
UL82 (A) and US3 (B) specific CD8+ T cells compared to UL83 (pp65) and UL123 723 
(IE1) specific cells respectively (expressed as a proportion of the Infected Control).  724 
Both UL82 and US3 specific CD8+ T cells are able to control dissemination of virus 725 
in this assay. 726 
 727 
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CMV301 53 M + 02 02 07 40 03 07 4/11 UL83 UL28, UL122, UL123
CMV302 56 M + 02 03 07 37 07 06 7/11 UL48, UL99, UL123 UL55, UL82, UL83, UL122
CMV303 29 M + 01 24 08 35 04 07 3/11 UL83, UL122, UL123
CMV304 41 M + 02 03 15 56 01 15 1/11 UL83
CMV305 25 M + 03 26 44 51 05 14 7/11
UL28, UL48, UL55, 
UL122, US3
UL82, UL123
CMV306 25 F + 01 29 08 27 07 16 1/10 UL122
CMV307 36 M + 01 26 08 27 01 07 9/11
UL48, UL55, UL82, UL83, 
UL99, UL122, US29
UL123
CMV308 72 M + 01 01 40 58 03 07 4/11 UL83, UL123, US32 UL122
CMV309 36 M + 01 23 35 37 04 06 6/11
UL48, UL55, UL82, 
UL122, US3
UL123
CMV311 32 M + 25 25 18 18 12 12 8/10
UL28, UL82, UL83, UL99, 
US3, US32
UL122, UL123
CMV312 77 M + 02 29 35 44 04 16 5/11 UL83, US3 UL82, UL122, UL123
CMV314 39 F + 30 74 14 50 08 06 4/11 UL83, UL122, US3, US32
CMV315 57 M + 01 32 07 13 07 06 8/11
UL48, UL55, UL82, UL99, 
US29
UL28, UL83, UL123
CMV316 65 M + 01 03 08 14 07 08 8/11
UL48, UL55, UL82, Ul122, 
US32
UL83, UL123, US3
CMV317 24 F + 01 31 35 51 07 14 4/11 UL83, UL123, US3 UL28
CMV318 39 M + 03 30 13 38 06 12 0/10
CMV320 50 F + 01 32 14 27 08 03 1/10 UL123
CMV400 55 M - 02 33 44 44 05 07 0/10
CMV401 45 M - 24 25 08 35 07 12 0/10
CMV405 35 F - 02 03 14 40 08 03 0/10
CMV406 24 M - 02 26 14 40 08 03 0/10
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CD8+ 
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IFNγ+
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IFNγ+
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CD8+ 
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% 
unact 
IFNγ+
% 
UL82+ 
IFNγ+
% 
CD8+ 
UL83+
% 
unact 
IFNγ+
% 
UL83+ 
IFNγ+
305 0.24 0.05 11.80 0.24 0.00 59.60 0.08 0.07 10.30
307 - - - 0.06 0.00 4.62 0.19 0.00 17.30
300 1.00 0.00 2.67 0.97 0.29 19.40 1.45 0.08 54.80
301 1.18 0.00 59.80 - - - 0.16 0.00 24.80
316 - - - - - - 0.11 0.02 12.10
312 - - - 0.54 0.00 11.10 0.03 0.03 13.20
Donor
% 
CD8+ 
UL122+
% 
unact 
IFNγ+
% 
UL122+ 
IFNγ+
% 
CD8+ 
UL123+
% 
unact 
IFNγ+
% 
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IFNγ+
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% 
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IFNγ+
% 
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IFNγ+
305 - - - 0.08 0.00 21.80 0.07 0.05 10.40
307 - - - 4.06 0.04 25.60 - - -
300 0.68 0.00 1.90 2.73 0.09 71.70 0.63 0.00 0.41
301 0.59 0.00 45.40 0.06 0.00 32.60 - - -
316 - - - 0.87 0.09 33.20 4.79 0.05 17.80
312 0.34 0.00 8.90 0.09 0.02 9.33 - - -
UL28 UL82 UL83
UL122 UL123 US3
CMV ORF specific CD8+ T cell Responses (4-1BB+ and CD69+)
 Donor CD28- CD57+ CD28- CD57+ CD28- CD57+ CD28- CD57+ CD28- CD57+ CD28- CD57+
305 90.40 19.20 69.70 32.80 59.50 40.50 - - 65.40 32.70 90.40 35.30
307 - - 94.10 29.40 96.70 60.00 - - 89.10 64.10 - -
300 73.90 77.50 73.70 61.40 78.60 58.80 76.60 80.40 75.90 86.50 75.70 68.10
301 86.10 53.50 - - 80.00 71.10 79.30 83.50 88.10 69.50 - -
316 - - - - 62.00 75.10 - - 61.10 77.90 62.30 68.80
312 - - 0.86 100.00 0.00 81.20 2.08 97.90 7.14 92.90 - -
UL123 US3UL28 UL82 UL83 UL122
 
Donor UNINF INF E:T 1.2:1 0.6:1 1.2:1 0.6:1 1.2:1 0.6:1
305 0.10 100.00 0.18 13.47 0.52 12.18 104.15 96.63
307 0.57 100.00 2.66 14.76 0.74 0.71 28.46 63.05
300 0.28 100.00 4.08 19.17 8.04 8.14 79.72 88.75
316 0.87 100.00 20.22 26.05 7.87 0.41 93.08 96.74
312 0.05 100.00 5.90 1.98 44.00 23.75 104.25 88.25
pp65 IE1 EBV
% Fibroblasts TB40e-UL32-GFP+ at Day 21
